1. Barnes TR. The Barnes akathisia rating scale–revisited. J Psychopharmacol.
2003;17(4):365e370.
2. Van Putten T. The many faces of akathisia. Compr Psychiatr. 1975;16(1):43e47.
3. Salem H, Nagpal C, Pigott T, Teixeira AL. Revisiting antipsychotic-induced
akathisia: current issues and prospective challenges. Curr Neuropharmacol.
2017;15(5):789e798.
4. Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, Soliman MA. The clinical challenges of
akathisia. CNS Spectr. 2015;20(Suppl 1):1e14. quiz 15e16.
5. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of
clinical features and response to open therapeutic trials. Mov Disord. 1989;4(2):
157e175.
6. Savitt D, Jankovic J. Tardive syndromes. J Neurol Sci. 2018;389:35e42.
7. Nagaoka K, Nagashima T, Asaoka N, et al. Striatal TRPV1 activation by acetaminophen ameliorates dopamine D2 receptor antagonist-induced orofacial
dyskinesia. JCI Insight. 2021;6(10), e145632.
8. Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah NH. A curated and
standardized adverse drug event resource to accelerate drug safety research.
Sci Data. 2016;3, 160026.
9. Nagashima T, Shirakawa H, Nakagawa T, Kaneko S. Prevention of
antipsychotic-induced hyperglycaemia by vitamin D: a data mining prediction followed by experimental exploration of the molecular mechanism. Sci
Rep. 2016;6, 26375.
10. Lai EC, Pratt N, Hsieh CY, et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol. 2017;32(7):
567e582.
11. Olmos A, Govindasamy P. Propensity scores: a practical introduction using R.
J Multidiscrip Eval. 2015;11(25):68e88.
12. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational
studies. Pharmaceut Stat. 2011;10(2):150e161.
Author contributions
Ko.N. performed clinical data analysis and animal experiments.
Ka.N. and H.S. provided materials and technical advice. Ko.N. and S.K.
designed the project, analyzed the data, and wrote the manuscript.
15
K. Nagaoka, K. Nagayasu, H. Shirakawa et al.
Journal of Pharmacological Sciences 151 (2023) 9e16
23. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy
and safety of individual second-generation vs. first-generation antipsychotics
in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205e1218.
24. Walters A, Hening W, Chokroverty S, Fahn S. Opioid responsiveness in patients
with neuroleptic-induced akathisia. Mov Disord. 1986;1(2):119e127.
25. Lublin H, Gerlach J, Mørkeberg F. Long-term treatment with low doses of
the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys
previously exposed to dopamine antagonists. Psychopharmacology.
1994;114(3):495e504.
26. Iyo M, Tadokoro S, Kanahara N, et al. Optimal extent of dopamine D2 receptor
occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis. J Clin Psychopharmacol. 2013;33(3):398e404.
27. Bordia T, Zhang D, Perez XA, Quik M. Striatal cholinergic interneurons and D2
receptor-expressing GABAergic medium spiny neurons regulate tardive
dyskinesia. Exp Neurol. 2016;286:32e39.
28. Tadokoro S, Okamura N, Sekine Y, Kanahara N, Hashimoto K, Iyo M. Chronic
treatment with aripiprazole prevents development of dopamine supersensitivity and potentially supersensitivity psychosis. Schizophr Bull. 2012;38(5):
1012e1020.
29. Oda Y, Fujita Y, Oishi K, et al. Alterations in glutamatergic signaling in the brain
of dopamine supersensitivity psychosis and non-supersensitivity psychosis
model rats. Psychopharmacology. 2017;234(20):3027e3036.
ski J. Paracetamol - an old drug with new
30. Przybyła GW, Szychowski KA, Gmin
mechanisms of action. Clin Exp Pharmacol Physiol. 2020;48(1):3e19.
rez J, et al. Hyperactivity induced by the
31. Luque-Rojas MJ, Galeano P, Sua
dopamine D2/D3 receptor agonist quinpirole is attenuated by inhibitors of
endocannabinoid degradation in mice. Int J Neuropsychopharmacol. 2013;16(3):
661e676.
13. Thomsen M, Fink-Jensen A, Woldbye DPD, et al. Effects of acute and chronic
aripiprazole treatment on choice between cocaine self-administration and food
under a concurrent schedule of reinforcement in rats. Psychopharmacology.
2008;201(1):43e53.
14. Oda Y, Tadokoro S, Takase M, et al. G protein-coupled receptor kinase 6/barrestin 2 system in a rat model of dopamine supersensitivity psychosis.
J Psychopharmacol. 2015;29(12):1308e1313.
15. Fleischhacker WW, Bergmann KJ, Perovich R, et al. The Hillside Akathisia Scale:
a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol
Bull. 1989;25(2):222e226.
16. Bleickardt CJ, Kazdoba TM, Jones NT, Hunter JC, Hodgson RA. Antagonism of the
adenosine A2A receptor attenuates akathisia-like behavior induced with MP10 or aripiprazole in a novel non-human primate model. Pharmacol Biochem
Behav. 2014;118:36e45.
17. Ehrenpreis ED, Deepak P, Sifuentes H, Devi R, Du H, Leikin JB. The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice,
adverse event reporting, and prescription drug lawsuits. Am J Gastroenterol.
2013;108(6):866e872.
18. Sieminski M, Zemojtel L. Akathisia is more than restlessness in the legs. J Clin
Sleep Med. 2019;15(9):1383.
19. Lyu S, Xing H, DeAndrade MP, et al. The role of BTBD9 in striatum and restless
legs syndrome. eNeuro. 2019;6(5), 0277-19.2019.
20. Qu S, Le W, Zhang X, Xie W, Zhang A, Ondo WG. Locomotion is increased in
a11-lesioned mice with iron deprivation: a possible animal model for restless
legs syndrome. J Neuropathol Exp Neurol. 2007;66(5):383e388.
21. Stahl SM, Lonnen AJ. The Mechanism of drug-induced akathsia. CNS Spectr.
2011;15. Stahl.
22. Mulroy E, Balint B, Bhatia KP. Tardive syndromes. Practical Neurol. 2020;20(5):
368e376.
16
...
論文の公開元へ
